{"id":63412,"date":"2026-04-20T14:06:58","date_gmt":"2026-04-20T06:06:58","guid":{"rendered":"https:\/\/flcube.com\/?p=63412"},"modified":"2026-04-20T14:06:59","modified_gmt":"2026-04-20T06:06:59","slug":"eli-lilly-in-advanced-talks-to-acquire-kelonia-therapeutics-for-over-2-billion-strengthening-car-t-cell-therapy-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63412","title":{"rendered":"Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion \u2013 Strengthening CAR-T Cell Therapy Portfolio"},"content":{"rendered":"\n<p><strong>Eli Lilly &amp; Co.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) is reportedly engaged in advanced negotiations to acquire <strong>Kelonia Therapeutics<\/strong>, a clinical-stage biotechnology company focused on gene medicines and <strong>CAR-T cell therapies<\/strong>, according to The Wall Street Journal. The potential transaction could value Kelonia at more than <strong>$2 billion<\/strong>, representing Lilly&#8217;s latest strategic move to expand beyond its dominant position in the obesity treatment market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Eli Lilly &amp; Co. (NYSE: LLY)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Kelonia Therapeutics (private)<\/td><\/tr><tr><td><strong>Deal Value<\/strong><\/td><td>&gt;$2 billion (reported)<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Gene medicines and CAR-T cell therapies<\/td><\/tr><tr><td><strong>Strategic Goal<\/strong><\/td><td>Bolster oncology portfolio and diversify beyond metabolic disorders<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>Advanced talks (not yet finalized)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-portfolio-enhancement-strategy\">Portfolio Enhancement Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Oncology Assets:<\/strong> Lilly&#8217;s existing cancer portfolio includes <strong>Jaypirca<\/strong> (pirtobrutinib) and the breast cancer drug <strong>Verzenio<\/strong> (abemaciclib), alongside other promising candidates in development.<\/li>\n\n\n\n<li><strong>Kelonia&#8217;s Innovation:<\/strong> The target company specializes in developing a pipeline of <strong>gene medicines<\/strong> with a particular emphasis on <strong>CAR-T cell therapies<\/strong> for various disease indications.<\/li>\n\n\n\n<li><strong>Market Positioning:<\/strong> The acquisition would enhance Lilly&#8217;s presence in the rapidly growing but highly competitive <strong>cancer treatment market<\/strong>, where cellular immunotherapies represent one of the most promising frontiers.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-expansion-beyond-obesity-dominance\">Expansion Beyond Obesity Dominance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic Area<\/th><th>Current Status<\/th><th>Strategic Direction<\/th><\/tr><\/thead><tbody><tr><td><strong>Obesity<\/strong><\/td><td>Market leader with blockbuster weight-loss drugs<\/td><td>Maintain dominance while diversifying<\/td><\/tr><tr><td><strong>Oncology<\/strong><\/td><td>Established portfolio with growth potential<\/td><td>Aggressively expand through acquisitions like Kelonia<\/td><\/tr><tr><td><strong>Inflammatory Bowel Disease<\/strong><\/td><td>Early-stage investments<\/td><td>Building pipeline through partnerships<\/td><\/tr><tr><td><strong>Ophthalmology<\/strong><\/td><td>Emerging focus area<\/td><td>Targeted acquisitions planned<\/td><\/tr><tr><td><strong>Gene Editing<\/strong><\/td><td>Initial exploration phase<\/td><td>Technology platform development through M&amp;A<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Lilly has been systematically expanding into high-value therapeutic areas beyond metabolic disorders, leveraging its strong cash flow from obesity treatments to fund strategic acquisitions and partnerships in adjacent markets with significant growth potential.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-competitive-landscape\">Market Impact &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CAR-T Cell Therapy Market:<\/strong> Valued at approximately <strong>$7.5 billion globally<\/strong> in 2025, with projected CAGR of 18.5% through 2030, driven by expanding indications and improved manufacturing processes.<\/li>\n\n\n\n<li><strong>Competitive Response:<\/strong> Major pharmaceutical competitors including <strong>Novartis<\/strong>, <strong>Bristol Myers Squibb<\/strong>, and <strong>Gilead Sciences<\/strong> have established CAR-T franchises, making Lilly&#8217;s entry through acquisition a logical strategic response.<\/li>\n\n\n\n<li><strong>Integration Benefits:<\/strong> Kelonia&#8217;s gene medicine platform could accelerate Lilly&#8217;s timeline to market leadership in cellular immunotherapy, providing critical capabilities in next-generation cancer therapies.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding potential acquisition discussions between Eli Lilly and Kelonia Therapeutics. Actual transactions may differ due to risks including negotiation outcomes, regulatory approvals, financing conditions, and competitive dynamics in the biotechnology sector.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly &amp; Co. (NYSE: LLY) is reportedly engaged in advanced negotiations to acquire Kelonia&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,199,4475,911],"class_list":["post-63412","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cancer","tag-eli-lilly","tag-kelonia-therapeutics","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion \u2013 Strengthening CAR-T Cell Therapy Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63412\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion \u2013 Strengthening CAR-T Cell Therapy Portfolio\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63412\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-20T06:06:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-20T06:06:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63412#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63412\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion \u2013 Strengthening CAR-T Cell Therapy Portfolio\",\"datePublished\":\"2026-04-20T06:06:58+00:00\",\"dateModified\":\"2026-04-20T06:06:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63412\"},\"wordCount\":421,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Eli Lilly\",\"Kelonia Therapeutics\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63412#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63412\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63412\",\"name\":\"Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion \u2013 Strengthening CAR-T Cell Therapy Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-20T06:06:58+00:00\",\"dateModified\":\"2026-04-20T06:06:59+00:00\",\"description\":\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63412#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63412\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63412#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion \u2013 Strengthening CAR-T Cell Therapy Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion \u2013 Strengthening CAR-T Cell Therapy Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63412","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion \u2013 Strengthening CAR-T Cell Therapy Portfolio","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=63412","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-20T06:06:58+00:00","article_modified_time":"2026-04-20T06:06:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63412#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63412"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion \u2013 Strengthening CAR-T Cell Therapy Portfolio","datePublished":"2026-04-20T06:06:58+00:00","dateModified":"2026-04-20T06:06:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63412"},"wordCount":421,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Eli Lilly","Kelonia Therapeutics","NYSE: LLY"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63412#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63412","url":"https:\/\/flcube.com\/?p=63412","name":"Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion \u2013 Strengthening CAR-T Cell Therapy Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-20T06:06:58+00:00","dateModified":"2026-04-20T06:06:59+00:00","description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63412#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63412"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63412#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion \u2013 Strengthening CAR-T Cell Therapy Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63412"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63412\/revisions"}],"predecessor-version":[{"id":63527,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63412\/revisions\/63527"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}